Related Experiment Video

Updated: Apr 21, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K

PI-3 kinase p110β: a therapeutic target in advanced prostate cancers

Benyi Li1, Aijing Sun2, Wencong Jiang3

  • 1Department of Urology, The University of Kansas Medical Center Kansas City, KS 66160, USA ; Department of Molecular & Integrative Physiology, The University of Kansas Medical Center Kansas City, KS 66160, USA ; Department of Pathology, Shaoxing People's Hospital Shaoxing 312000, China ; Department of Urology, Guangdong Medical College Zhanjiang 524001, China.

American Journal of Clinical and Experimental Urology
|November 7, 2014
PubMed

Insights

Novel therapies are needed for advanced prostate cancer. Phosphoinositide 3-kinase p110β (PI3K p110β) is overexpressed in prostate cancer and is a promising therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Castration-resistant prostate cancer (CRPC) is a life-threatening, incurable stage of prostate cancer.
  • Current treatments like Enzalutamide and Abiraterone offer limited survival benefits in advanced prostate cancer.
  • Novel therapeutic strategies are urgently required for effective CRPC management.

Purpose of the Study:

  • To review recent developments in targeting phosphoinositide 3-kinases (PI3K) for advanced prostate cancer.
  • To highlight the role of PI3K p110β as a critical oncogene in prostate cancer progression.
  • To discuss the potential of novel p110β-specific inhibitors as therapeutic agents.

Main Methods:

  • Literature review of studies on PI3K signaling in cancer.
  • Summary of evidence implicating PI3K p110β in prostate cancer development and progression.
  • Overview of preclinical and clinical investigations of p110β inhibitors.

Main Results:

  • Phosphoinositide 3-kinases (PI3K) are key regulators of cell signaling pathways involved in cancer.
  • Aberrant overexpression of PI3K p110β isoform is observed in advanced prostate cancers.
  • PI3K p110β plays a critical role in prostate cancer development and progression, as shown in cell and animal models.

Conclusions:

  • PI3K p110β is a validated oncogenic driver in advanced prostate cancer.
  • Novel p110β-specific inhibitors represent a promising therapeutic avenue for CRPC.
  • Targeting PI3K p110β warrants further clinical investigation for advanced prostate cancer treatment.
Keywords:
Prostate cancercancer therapycastration resistancep110β

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.2K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.6K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
628
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
673